Gabriele Giacomo Schiattarella1,2, Anna Sannino1,3, Evelina Toscano1, Giuseppe Giugliano1, Giuseppe Gargiulo1,4, Anna Franzone1,4, Bruno Trimarco1, Giovanni Esposito1, Cinzia Perrino1. 1. Department of Advanced Biomedical Sciences, Federico II University, Via Pansini 5, 80131 Naples, Italy. 2. Department of Internal Medicine, Cardiology, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, 75390-8573 Dallas, TX, USA. 3. Baylor Heart and Vascular Hospital, Baylor Research Institute, Department of Cardiology, 621 North Hall Street, 75226 Dallas, TX, USA. 4. Department of Cardiology, Bern University Hospital, Freiburgstrasse 4, 3010 Bern, Switzerland.
Abstract
AIMS: Gut microbiota-derived metabolite trimethylamine-N-oxide (TMAO) is emerging as a new potentially important cause of increased cardiovascular risk. The purpose of this meta-analysis was to systematically estimate and quantify the association between TMAO plasma levels, mortality, and major adverse cardio and cerebrovascular events (MACCE). METHODS AND RESULTS: MEDLINE, ISI Web of Science, and SCOPUS databases were searched for ad hoc studies published up to April 2017. Associations between TMAO plasma levels, all-cause mortality (primary outcome) and MACCE (secondary outcome) were systematically addressed. A total of 17 clinical studies were included in the analytic synthesis, enrolling 26 167 subjects. The mean follow-up in our study population was 4.3 ± 1.5 years. High TMAO plasma levels were associated with increased incidence of all-cause mortality [14 studies for 16 cohorts enrolling 15 662 subjects, hazard ratio (HR): 1.91; 95% confidence interval (CI): 1.40-2.61, P < 0.0001, I2 = 94%] and MACCE (5 studies for 6 cohorts enrolling 13 944 subjects, HR: 1.67, 95% CI: 1.33-2.11, P < 0.00001, I2 = 46%,). Dose-response meta-analysis revealed that the relative risk (RR) for all-cause mortality increased by 7.6% per each 10 μmol/L increment of TMAO [summary RR: 1.07, 95% CI (1.04-1.11), P < 0.0001; based on seven studies]. Association of TMAO and mortality persisted in all examined subgroups and across all subject populations. CONCLUSIONS: This is the first systematic review and meta-analysis demonstrating the positive dose-dependent association between TMAO plasma levels and increased cardiovascular risk and mortality. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Gut microbiota-derived metabolite trimethylamine-N-oxide (TMAO) is emerging as a new potentially important cause of increased cardiovascular risk. The purpose of this meta-analysis was to systematically estimate and quantify the association between TMAO plasma levels, mortality, and major adverse cardio and cerebrovascular events (MACCE). METHODS AND RESULTS: MEDLINE, ISI Web of Science, and SCOPUS databases were searched for ad hoc studies published up to April 2017. Associations between TMAO plasma levels, all-cause mortality (primary outcome) and MACCE (secondary outcome) were systematically addressed. A total of 17 clinical studies were included in the analytic synthesis, enrolling 26 167 subjects. The mean follow-up in our study population was 4.3 ± 1.5 years. High TMAO plasma levels were associated with increased incidence of all-cause mortality [14 studies for 16 cohorts enrolling 15 662 subjects, hazard ratio (HR): 1.91; 95% confidence interval (CI): 1.40-2.61, P < 0.0001, I2 = 94%] and MACCE (5 studies for 6 cohorts enrolling 13 944 subjects, HR: 1.67, 95% CI: 1.33-2.11, P < 0.00001, I2 = 46%,). Dose-response meta-analysis revealed that the relative risk (RR) for all-cause mortality increased by 7.6% per each 10 μmol/L increment of TMAO [summary RR: 1.07, 95% CI (1.04-1.11), P < 0.0001; based on seven studies]. Association of TMAO and mortality persisted in all examined subgroups and across all subject populations. CONCLUSIONS: This is the first systematic review and meta-analysis demonstrating the positive dose-dependent association between TMAO plasma levels and increased cardiovascular risk and mortality. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Paolo Marzullo; Laura Di Renzo; Gabriella Pugliese; Martina De Siena; Luigi Barrea; Giovanna Muscogiuri; Annamaria Colao; Silvia Savastano Journal: Int J Obes Suppl Date: 2020-07-20
Authors: Robert A Koeth; Betzabe Rachel Lam-Galvez; Jennifer Kirsop; Zeneng Wang; Bruce S Levison; Xiaodong Gu; Matthew F Copeland; David Bartlett; David B Cody; Hong J Dai; Miranda K Culley; Xinmin S Li; Xiaoming Fu; Yuping Wu; Lin Li; Joseph A DiDonato; W H Wilson Tang; Jose Carlos Garcia-Garcia; Stanley L Hazen Journal: J Clin Invest Date: 2018-12-10 Impact factor: 14.808
Authors: G Latkovskis; E Makarova; M Mazule; L Bondare; D Hartmane; H Cirule; S Grinberga; A Erglis; E Liepinsh; M Dambrova Journal: Br J Clin Pharmacol Date: 2018-09-06 Impact factor: 4.335
Authors: Michael C Petriello; Richard Charnigo; Manjula Sunkara; Sony Soman; Marian Pavuk; Linda Birnbaum; Andrew J Morris; Bernhard Hennig Journal: Environ Res Date: 2018-01-30 Impact factor: 6.498
Authors: Sarah M Skye; Weifei Zhu; Kymberleigh A Romano; Chun-Jun Guo; Zeneng Wang; Xun Jia; Jennifer Kirsop; Bridget Haag; Jennifer M Lang; Joseph A DiDonato; W H Wilson Tang; Aldons J Lusis; Federico E Rey; Michael A Fischbach; Stanley L Hazen Journal: Circ Res Date: 2018-10-26 Impact factor: 17.367